Art. -Nr.: HY-D0143

Quinine

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Quinine is an orally active alkaloid extracted from cinchona bark, possessing various biological activities including antimalarial, antidengue virus (DENV), and anticancer properties. Quinine is a potassium channel inhibitor that inhibits WT mouse Slo3 (K_Ca5.1) channel currents evoked by voltage pulses to +100 mV with an IC₅₀ of 169 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.82%
CAS. Nr.: 130-95-0
Formel: C₂₀H₂₄N₂O₂
Molecular Weight:324.42

Speicherung:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Quinine Chemical Structure

CAS. Nr.: 130-95-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Plasmodium

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	>50 μM Compound: 2	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
A-431	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
EJ	IC₅₀	>50 μM Compound: 2	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
FM3A	EC₅₀	0.0001 M Compound: Quinine	In vitro cytotoxic activity against mouse mammary tumor FM3A cells In vitro cytotoxic activity against mouse mammary tumor FM3A cells	[PMID: 10937718]
FM3A	EC₅₀	0.1 mM Compound: Quinine	In vitro cytotoxic activity against mouse mammary tumor FM3A cells In vitro cytotoxic activity against mouse mammary tumor FM3A cells	[PMID: 10937718]
FM3A	EC₅₀	0.0001 M Compound: Quinine	Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host	[PMID: 11855978]
FM3A	EC₅₀	0.1 mM Compound: Quinine	Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host	[PMID: 11855978]
FM3A	EC₅₀	0.0001 M Compound: Quinine	In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells	[PMID: 15026051]
FM3A	EC₅₀	0.1 mM Compound: Quinine	In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells	[PMID: 15026051]
FM3A	EC₅₀	100 μM Compound: quinine	Cytotoxicity against mouse FM3A cell line Cytotoxicity against mouse FM3A cell line	[PMID: 16524728]
HEK293	IC₅₀	0.9 μM Compound: Quinine	TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells	[PMID: 12438515]
HEK293	IC₅₀	1.1 μM Compound: Quinine	TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells	[PMID: 12438515]
HEK293	IC₅₀	13 μM Compound: Quinine	TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells	[PMID: 12438515]
HEK293	IC₅₀	38 μM Compound: Quinine	TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells	[PMID: 12438515]
HEK293	IC₅₀	51.6 μM Compound: quinine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HEK293	IC₅₀	275.6 μM Compound: Quinine	Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay	[PMID: 28027871]
HEK293	IC₅₀	134.35 μM Compound: Quinine	Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay	[PMID: 33744688]
HeLa	IC₅₀	>50 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
Hepatocyte	IC₅₀	150 μM Compound: 11 Quinine	Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes	[PMID: 15225721]
HepG2	CC₅₀	>100 μM Compound: 3	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 30779564]
HT-1080	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
Huh-7	CC₅₀	>6.25 μM Compound: GNF-Pf-180	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Jurkat	IC₅₀	>50 μM Compound: 2	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
KB	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 11421741]
KB	IC₅₀	>20000 ng/mL Compound: quinine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 1294700]
KB	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 16933872]
KB	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
KB	IC₅₀	>20000 ng/mL Compound: Quinine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8759172]
KB	IC₅₀	>20000 ng/mL Compound: quinine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 9134742]
KB	ED₅₀	>55400 nM Compound: quinine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 9917283]
KB-V1	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human multidrug-resistant KBV1 cells Cytotoxicity against human multidrug-resistant KBV1 cells	[PMID: 8450318]
KB-V1	ED₅₀	5.6 μg/mL Compound: quinine	Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
LNCaP	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
MES-SA	IC₅₀	91 μM Compound: 2; Q	Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay	[PMID: 35640378]
MES-SA	IC₅₀	93 μM Compound: 2; Q	Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay	[PMID: 35640378]
MES-SA/Dx5	IC₅₀	43 μM Compound: 2; Q	Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs in presence of P-gp inhibitor Tariquidar by fluorescence microplate reader assay	[PMID: 35640378]
MES-SA/Dx5	IC₅₀	67 μM Compound: 2; Q	Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 144 hrs by fluorescence microplate reader assay	[PMID: 35640378]
NIH-3T3-G185	IC₅₀	112.4 μM Compound: Quinine	TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	159.3 μM Compound: Quinine	TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	167.8 μM Compound: Quinine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	184.9 μM Compound: Quinine	TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	22.6 μM Compound: Quinine	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	74.4 μM Compound: Quinine	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	87.6 μM Compound: Quinine	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
Oocyte	IC₅₀	4.1 μM Compound: Quinine	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes	[PMID: 11502595]
P388	ED₅₀	>5 μg/mL Compound: quinine	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 8450318]
P388	ED₅₀	>5 μg/mL Compound: quinine	Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay	[PMID: 8450319]
PC-3	IC₅₀	>50 μM Compound: 2	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
ScN2a	IC₅₀	10 μM Compound: quinine	Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation	[PMID: 17850126]
SK-MEL-2	ED₅₀	>20 μg/mL Compound: quinine	Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay	[PMID: 8450319]
WI-38	IC₅₀	6.56 μg/mL Compound: 1a	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 23816880]
WI-38	IC₅₀	20.25 μM Compound: QN	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 26063305]
ZR-75-1	ED₅₀	1.2 μg/mL Compound: quinine	Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay	[PMID: 8450319]

In Vitro

Quinine (150 μM, 30 min) inhibits the proliferation and cytostatic effects of DENV (Dengue virus) in human hepatocarcinoma HepG2 cell line^[1].
Quinine (37.5-150 μM, 24 hours) significantly reduces viral DENV RNA and protein levels in a dose-dependent manner in human hepatocarcinoma HepG2 cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Human hepatocarcinoma cell line (HepG2)
Concentration:

150 μM
Incubation Time:

30 min
Result:

Inhibited DENV virus replication with 19% yield compared to untreated. Reduced DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner.

In Vivo

Quinine (oral gavage, 12 or 15 mg/kg, every week, 16 weeks) has some tumor suppressing effect on skin cancer in Swiss albino mice^[2].
Quinine (oral gavage, 10 mg/kg, everyday, 8 weeks) causes a decrease in the antioxidant defense system of rat testicular tissue such as SOD, CAT and GSH enzyme activity in male adult albino rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss albino mice 7-8-weeks (weighing 24 g)^[2]
Dosage:

12 mg/kg, 15 mg/kg
Administration:

Oral gavage; every week; 16 weeks
Result:

Resulted in a significant reduction in tumor size and weight at 12 mg/kg and little effect at higher dose of 15 mg/kg.

Chemical Information

CAS. Nr. 130-95-0
Appearance Solid
Molecular Weight 324.42
Formel C₂₀H₂₄N₂O₂
Color White to off-white
SMILES

O[C@H](C1=CC=NC2=C1C=C(OC)C=C2)[C@@]3([H])[N@](C[C@@H]4C=C)CC[C@H]4C3
Structure Classification
- Alkaloids
- Quinoline Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (7)

All

Sort by:

Journal Impact Factor

Cell Mol Life Sci

The contrasting effects of two antimalarial drugs on insulin secretion. [Abstract]

2025 Nov 25;82(1):419. PMID: 41288707
J Mol Cell Biol

Low-dose quinine targets KCNH6 to potentiate glucose-induced insulin secretion. [Abstract]

2025 Jan 23:mjae051. PMID: 39848918
Neurosci Bull

A Novel Functional Method of Protector Screening for Zebrafish Lateral Line Hair Cells via the Acoustic Escape Response. [Abstract]

2025 May 6. PMID: 40329138
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Mol Med Rep

Therapeutic effects of quinine in a mouse model of atopic dermatitis. [Abstract]

2021 May;23(5):313. PMID: 34240224
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Norwegian University of Science and Technology

2019 Sep.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (308.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0824 mL

15.4121 mL

30.8242 mL

5 mM

0.6165 mL

3.0824 mL

6.1648 mL

10 mM

0.3082 mL

1.5412 mL

3.0824 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jhanwar, Deepika，et al. Chemoprevention of DMBA induced skin carcinogenesis in swiss albino mice by quinine sulfate.(2016): 2636-2640.

[2]. Shilu Malakar，et al. Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res. 2018 Aug 15;255:171-178. doi: 10.1016/j.virusres.2018.07.018. Epub 2018 Jul 25. [Content Brief]

[3]. Ebenezer O Farombi, et al. Quercetin protects against testicular toxicity induced by chronic administration of therapeutic dose of quinine sulfate in rats. J Basic Clin Physiol Pharmacol. 2012 Feb 27;23(1):39-44. [Content Brief]

[4]. Jane Achan , et al. Quinine, an Old Anti-Malarial Drug in a Modern World: Role in the Treatment of Malaria. Malar J. 2011 May 24;10:144. [Content Brief]

[5]. Wrighton DC, et al. Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium. Br J Pharmacol. 2015 Sep;172(17):4355-63. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0824 mL	15.4121 mL	30.8242 mL	77.0606 mL
	5 mM	0.6165 mL	3.0824 mL	6.1648 mL	15.4121 mL
	10 mM	0.3082 mL	1.5412 mL	3.0824 mL	7.7061 mL
	15 mM	0.2055 mL	1.0275 mL	2.0549 mL	5.1374 mL
	20 mM	0.1541 mL	0.7706 mL	1.5412 mL	3.8530 mL
	25 mM	0.1233 mL	0.6165 mL	1.2330 mL	3.0824 mL
	30 mM	0.1027 mL	0.5137 mL	1.0275 mL	2.5687 mL
	40 mM	0.0771 mL	0.3853 mL	0.7706 mL	1.9265 mL
	50 mM	0.0616 mL	0.3082 mL	0.6165 mL	1.5412 mL
	60 mM	0.0514 mL	0.2569 mL	0.5137 mL	1.2843 mL
	80 mM	0.0385 mL	0.1927 mL	0.3853 mL	0.9633 mL
	100 mM	0.0308 mL	0.1541 mL	0.3082 mL	0.7706 mL

Keywords

Quinine

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Quinine

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Quinine

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Quinine

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Quinine

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Quinine Related Classifications

HY-D0143 Related Classifications